Hudson Bay Capital Management’s Myriad Genetics MYGN Stock Holding History

Hudson Bay Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,284	Closed	-$164K	–	942
2022 Q4	$164K	Buy	+11,284	New	+$210K	﹤0.01%	753
2019 Q4	–	Sell	-35,000	Closed	-$1M	–	475
2019 Q3	$1M	Sell	35,000 -15,000	-30%	-$437K	0.03%	319
2019 Q2	$1.39M	Buy	+50,000	New	+$1.41M	0.03%	306
2018 Q2	–	Sell	-50,000	Closed	-$1.48M	–	923
2018 Q1	$1.48M	Buy	+50,000	New	+$1.69M	0.03%	507

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Hudson Bay Capital Management's MYGN Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 11,284 shares — an estimated $164K sold.

Hudson Bay Capital Management first reported a position in MYGN in Q1 2018 and held it in 4 quarters. The position peaked at $1.48M in Q1 2018. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Hudson Bay Capital Management reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 11,284 Myriad Genetics shares in Q1 2023, an estimated $164K.
Hudson Bay Capital Management first reported a position in Myriad Genetics in Q1 2018 and held it in 4 quarters.
Hudson Bay Capital Management's Myriad Genetics position peaked at $1.48M in Q1 2018.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.